Yahoo Suche Web Suche

  1. Wertvolle Berufserfahrung neben dem Bachelorabschluss sammeln: Duales Studium der FOM. Doppelt so gut ins Berufsleben starten: Mit den dualen Studiengängen der FOM. Infos hier.

Suchergebnisse

  1. Suchergebnisse:
  1. Vor 5 Stunden · Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies , a clinical-stage biopharmaceutical company focused on treatment options for food...

  2. Vor einem Tag · The event will feature Alexander Eggermont, MD, PhD (University Medical Center Utrecht), who will join company management to discuss the recently disclosed positive clinical data for BioInvent's lead, first-in-class antibodies, BI-1808 and BI-1206, to be presented at ASCO and EHA. The data support the promise of FcyRIIB and TNFR2 as important immunotherapy targets. BI-1808 and BI-1206 are ...

  3. Vor einem Tag · "Reinventing Sound" by Michael Prins happening at 's-Gravendijkwal 127 a, 3021 EK Rotterdam, Netherlands, 's-Gravendijkwal 125C-01, 3021 EK Rotterdam, Nederland,Rotterdam, Netherlands on Thu May 30 2024 at 06:00 pm

  4. Vor einem Tag · The event will feature Alexander Eggermont, MD, PhD (University Medical Center Utrecht), who will join company management to discuss the recently disclosed positive clinical data for BioInvent’s lead, first-in-class antibodies, BI-1808 and BI-1206, to be presented at ASCO and EHA. The data support the promise of FcyRIIB and TNFR2 as important immunotherapy targets. BI-1808 and BI-1206 are ...

  5. Vor einem Tag · A flash talk presentation by Nicolette Arends, M.D., Erasmus University Rotterdam will describe data collected on accidental peanut consumption from DBV’s EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 through 3 years. DBV will also host a symposium and exhibit booth in the EAACI exhibit hall.

  6. Vor 5 Stunden · A flash talk presentation by Nicolette Arends, M.D., Erasmus University Rotterdam will describe data collected on accidental peanut consumption from DBV’s EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 through 3 years. DBV will also host a symposium and exhibit booth in the EAACI exhibit hall.